Is cystatin C a useful marker in the detection of diabetic kidney disease?

Nephron - Clinical Practice

Volumn 114, Issue 2, 2010, Pages

  Borges, Rodolfo L ^a   Hirota, Andréa H ^a   Quinto, Beata M R ^a   Ribeiro, Arthur B ^a   Zanella, Maria T ^a   Batista, Marcelo C ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cystatin C; Diabetes type 2; Diabetic nephropathy; Hypertension

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; CYSTATIN C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THYROTROPIN; TRIACYLGLYCEROL;

ABDOMINAL AORTA ANEURYSM; ADULT; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CAROTID ARTERY DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY SURGERY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE MARKER; ENZYME IMMUNOASSAY; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; ISOTOPE DILUTION ASSAY; KIDNEY DYSFUNCTION; KIDNEY FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STABLE ANGINA PECTORIS; THYROTROPIN BLOOD LEVEL; TRANSLUMINAL CORONARY ANGIOPLASTY; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS; URIC ACID BLOOD LEVEL; URINALYSIS;

BIOLOGICAL MARKERS; BRAZIL; CYSTATIN C; DIABETIC NEPHROPATHIES; DIAGNOSIS, COMPUTER-ASSISTED; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 70350536900     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000254385     Document Type: Article

References (40)

1. Zimmet P, Alberti KG, Shaw J: Global and societal implications of the diabetes epidemic. Nature 2001;414:782-787.
2. Kassirer JP: Clinical evaluation of kidney function: glomerular function. N Engl J Med 1971;285:385-389.
3. Levey AS: Measurement of renal function in chronic renal disease. Kidney Int 1990;38:167-184.
4. Perrone RD, Madias NE, Levey AS: Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992;38:1933-1953.
5. National Kidney Foundation: D/DOQI Clinical practice guideline to define chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002;39:S1-S266.
6. Abrahamson M, Olafsson I, Palsdottir A, Ulvsbäck M, Lundwall A, Jensson O, Grubb A: Structure and expression of the human cystatin C gene. Biochem J 1990;268:287-94.
7. Fliser D, Ritz E: Serum cystatin C concentration as a marker of renal dysfunction in the elderly Am J Kidney Dis 2001;37:79-83.
8. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, Price CP: Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995;47:312-318.
9. Fried LF, Katz R, Sarnak MJ, Shlipak MG, Chaves PH, Jenny NS, Stehman-Breen C, Gillen D, Bleyer AJ, Hirsch C, Siscovick D, Newman AB: Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol 2005;16:3728-3735.
10. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C: Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005;352:2049-2060.
11. Shlipak MG, Wassel Fyr CL, Chertow GM, Harris TB, Kritchevsky SB, Tylavsky FA, Satterfield S, Cummings SR, Newman AB, Fried LF: Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol 2006;17:254-261.
12. American Diabetes Association: Standards of Medical Care in Diabetes - 2006. Diabetes Care 2006;29:S4-S85.
13. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, Steffes MW: Nephropathy in diabetes. Diabetes Care 2004;27:S79-S83.
14. Fioretto P, Mauer M, Brocco E, Velussi M, Frigato F, Muollo B, Sambataro M, Abaterusso C, Baggio B, Crepaldi G, Nosadini R: Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1996;1569-1576.
15. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
16. DuBois D, DuBois EF: A formula to estimate the approximate surface area if height and weight are known. Ann Intern Med 1916;17:863-871.
17. Köttgen A, Selvin E, Stevens LA, Levey AS, Lente VF, Coresh J: Serum cystatin C in the United States: The Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2008;51:385-394.
18. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final report. Circulation 2002;106:3143-3421.
19. Alberti KG, Zimmet P, Shaw J: Metabolic syndrome: a new world-wide definition: a consensus statement from the International Diabetes Federation. Diabet Med 2006;23:469-480.
20. Myers G, Miller W, Coresh J, Fleming J, Greenberg N, Greene T, Hostetter T, Levey AS, Panteghini M, Welch M, Eckfeldt JH: Recommendations for improving serum creatinine measurement: a report from the laboratory working group of the National Kidney Disease Education Program. Clin Chem 2006;52:5-18.
21. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, Seliger SL, Kestenbaum B, Psaty B, Tracy RP, Siscovick DS: Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006;145:237-246.
22. Levey SA, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Lente FV: Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007;53:766-772.
23. Mussap M, Vestra DM, Fioretto P, Saller A, Varagnolo M, Nosadini R, Plebani M: Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int 2002;61:1453-1461.
24. Hojs R, Bevc S, Ekart R, Gorenjak M, Puklavec L: Serum cystatin C as an endogenous marker of renal function in patients with mild to moderate impairment of kidney function. Nephrol Dial Transplant 2006;21:1855-1862.
25. Dharnidharka VR, Kwon C, Stevens G: Serum cystatin C is superior to serum creatinine as a marker of kidney function: a metaanalysis. Am J Kidney Dis 2002;40:221-226.
26. Perkins BA, Nelson RG, Ostrander BEP, Blouch KL, Krolewski AS, Myers BD, Warram JH: Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol 2005;16:1404-1412.
27. National Kidney Foundation: K/DOQI Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49:S1-S179.
28. Parving HH, Chaturvedi N, Viberti G, Mogersen CE: Does microalbuminuria predict diabetic nephropathy? Diabetes Care 2002;25:406-407.
29. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR: Risk factors for renal dysfunction in type 2 diabetes. Diabetes 2006;55:1832-1839.
30. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653.
31. Kurella M, Lo JC, Chertow GM: Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005;16:2134-2140.
32. Ryu S, Chang Y, Woo HY, Lee KB, Kim SG, Kim DI, Kim WS, Suh BS, Jeong C, Yoon K: Time-dependent association between metabolic syndrome and risk of CKD in Korean men without hypertension or diabetes. Am J Kidney Dis 2009;53:59-69.
33. Servais A, Giral P, Bernard M, Bruckert E, Deray G, Isnard Bagnis C: Is serum cystatin-C a reliable marker for metabolic syndrome? Am J Med 2008;121:426-432.
34. Nosadini R, Carboni A, Manconi A, Angius F, Carla S, Cherchi S, Satta A, Faedda F, Obinu D, Nieddu M, Carraro A, Tonolo GC: The decline of glomerular function is not always associated with the development of micro- and macroalbuminuria in hypertensive patients with type 2 diabetes. Diabetologia 2008 DOI: 10.1007/s00125-008-1079-8.
35. Parikh NI, Hwang SJ, Yang Q, Larson MG, Guo CY, Robins SJ, Sutherland P, Benjamin EJ, Levy D, Fox CS: Clinical correlates and heritability of cystatin C (from the Framingham Offspring Study). Am J Cardiol 2008;102:1194-1198.
36. Chudleigh RA, Dunseath G, Peter R, Harvey JN, Ollerton RL, Luzio S, Owens DR: Influence of body weight on the performance of glomerular filtration rate estimators in subjects with type 2 diabetes. Diabetes Care 2008;31:47-49.
37. Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, de Jonq PE: Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004;65:1416-1421.
38. Galteau MM, Guyon M, Gueguen R, Siest G: Determination of serum cystatin C: biological variation and reference values. Clin Chem Lab Med 2001;39:850-857.
39. Muntner P, Winston J, Uribarri J, Mann D, Fox CS: Overweight, obesity, and elevated serum cystatin C levels in adults in the United States. Am J Med 2008;121:341-348.
40. Naour N, Fellahi S, Renucci JF, Poitou C, Rouault C, Basdevant A, Dutour A, Alessi MC, Bastard JP, Clément K, Guerre-Millo M: Potential contribution of adipose tissue to elevated serum cystatin c in human obesity. Obesity 2009 DOI: 10.1038/oby.2009.96.